Introduction
Retinoids, such as all-trans-retinoic acid (ATRA), exert a wide range of eects on both normal and malignant cells. Although explored as a potential therapeutic and/ or chemopreventive agent in a number of human cancers, clinical use of ATRA has never been more successful than in the treatment of acute promyelocytic leukemia (APL). Actions of ATRA and wide range of other natural or synthetic retinoids, are mediated through binding to speci®c nuclear receptors (NRs) that regulate gene transcription (Glass and Rosenfeld, 2000) . To date, three dierent retinoic acid receptor (RAR) and retinoid X (or rexinoid) receptor (RXR) genes have been characterized, each encoding multiple Nterminal protein isoforms (Chambon, 1996) . RXRs serve as obligatory heterodimerization partners for RARs and for a number of other NRs including those for thyroid hormones (TR) and vitamin D 3 (VDR), thus integrating dierent signaling pathways (Chambon, 1996; Glass and Rosenfeld, 2000) . RARs, like many other members of the NR superfamily (Chambon, 1996; Mangelsdorf and Evans, 1995) , can activate or repress transcription of their target genes. Transcriptional repression and activation by RARs involves recruitment of multiprotein co-activator and co-repressor complexes with histone acetytransferase (HAT) and histone deacetylase (HDAC) activities respectively. Binding of ATRA to RAR provides a molecular switch that turns its activity from a repressor to an activator of gene transcription (Glass and Rosenfeld, 2000) .
Given its responsiveness to ATRA, the discovery that the t(15;17) translocation, a cytogenetic marker for APL (Rowley et al., 1977) , involves a fusion of the RARa gene on chromosome 17q21 to a locus called PML (Borrow et al., 1990; de The et al., 1990; Longo et al., 1990; Miller et al., 1990 ) appeared rather paradoxical. However, subsequent studies addressing the function of the resulting PML ± RARa fusion oncoprotein had clearly indicated that the therapeutic eects of ATRA in this disease are due to its direct action on the activity of PML ± RARa Guidez et al., 1998; He et al., 1998; Hong et al., 1997; Lin et al., 1998) . In addition to the PML/RARa rearrangement, four other APL associated translocations of the RARa gene have been characterized to date at the molecular level. The t(5;17)(q35;q21) (Redner et al., 1996b) , t(11;17)(q23;q21) (Chen et al., 1993b) , t(11;17)(q13;q21) (Wells et al., 1997) and t(17;17)(q11;q21) (Arnould et al., 1999) fuse RARa to the Nucleophosmin (NPM), Promyelocytic Leukeia Zinc Finger (PLZF), Nuclear Mitotic Apparatus (NuMA) and STAT5b genes, respectively. As in the case of t(15;17) translocation, the above rearrangements of RARa lead to expression of PLZF-, NPM-, NuMAand STAT5b-RARa fusion proteins (see Figure 1 for a schematic representation). Common features of all these proteins are B through F regions of RARa, which contain its DNA and ligand binding domains (DBD and LBD, respectively) , with non-RAR Nterminal moieties that contribute additional dimerization motifs to the fusion proteins. These heterologous dimerization domains promote formation of chimeric receptor homodimers, thus removing requirement of RXR for binding to DNA Perez et al., 1993) , and together with the DNA binding domain of RARa appear to be required for oncogenic activities of the fusion proteins (Lin and Evans, 2000; .
Rearrangement between the RARa and PML genes
The human and mouse RARa genes have been cloned and partially characterized (Brand et al., 1990; Leroy et al., 1991) . They each contain 10 exons and two promoters, which control expression of two major isoforms (RARa1 and RARa2) that dier in the sequences corresponding to their 5'-untranslated (5'-UTR) and A regions. The B to F region sequences, however, are common to both isoforms (see Figure 2 for a schematic representations). Although expression of the RARa1 isoform is ubiquitous, the RARa2 isoform is expressed in an ATRA-dependent and tissue-speci®c manner (Leroy et al., 1991) . In addition, during myeloid dierentiation of a multipotent murine progenitor cell line (FDCPmixA4) expression of both RARa1 and 2 isoforms becomes restricted to the myelomonocytic lineage .
The PML gene encodes a nuclear protein with a characteristic zinc-®nger motif called the RING ®nger (Reddy et al., 1992) . The human PML gene is comprised of 9 exons with exons 7 ± 9 having potential to generate by alternative splicing a number of Cterminally divergent PML isoforms. Exact functions of these isoforms are not clear, but the C-termini of PML are rich in proline/serine residues and contain a number of potential phosphorylation sites de The et al., 1991; Fagioli et al., 1992; Goddard et al., 1991; Kakizuka et al., 1991) . Furthermore, C-terminal sequences for speci®c PML isoforms have been shown to play a role in regulation of PML stability (Lallemand-Breitenbach et al., 2001) and interaction with the p53 tumour suppressor protein (Ferbeyre et al., 2000; Fogal et al., 2000; Guo et al., 2000; Pearson et al., 2000) . The PML gene is Figure 1 Schematic representation of RARa and four APL associated RARa fusion proteins. RARa functional domains (a ± f) are as indicated. Open triangles denote boundaries between sequences encoded in separate exons lying on opposite sides of a given translocation breakpoint. Dierent patterns and colors are used to represent various functional regions of the PML, PLZF, NPM, NuMA and STAT5b proteins. Circled Zn 2+ symbols and PML regions labelled as RING, B1 and B2 represent two of the nine kruÈ ppel-like Zn-®nger motifs and cystein-histidine rich domains in the PLZF and PML proteins, respectively. Light red regions (labeled Coiled-coil in PML and STAT5b, and POZ in PLZF) represent protein-protein interaction motifs present in N-termini of all the RARa chimeras. Relative positions of STAT5b DNA binding (DBD), SH3 and SH2 domains are also indicated Figure 2 Schematic representation of the RARa gene and the RARa1 and a2 isoforms. Exons are represented by shaded boxes and are numbered consecutively. Regions that are not shaded represent 5' and 3' untranslated sequences (UTR). Two promoters, P1 and P2, are indicated by broken arrows. Presence of a retinoic acid reponse element (RARE) in P2 is indicated. Positions of translocation breakpoints within the RARa gene are indicated with horizontal arrows. Number of arrows re¯ects relative frequency of breakpoints in introns 1 (infrequent), 2 (most frequent) and 3 (less frequent). Protein coding sequences are indicated by shaded rectangles and are subdivided into conserved (B ± F) and divergent (A regions) functional domains. Dierent shadings are used to represent RAR isoform-speci®c sequences. Regions encoded by dierent exons are indicated by arrowheads underneath each diagram. DNA (DBD) and ligand (LBD) binding domains (regions C and E, respectively) are indicated above the scheme for each isoform ubiquitously expressed, albeit at dierent levels (Goddard et al., 1991) , which is reminiscent of RARa1 expression. PML levels can be upregulated by interferons (Stadler et al., 1995) , higher levels of PML expression were found in some solid tumors Terris et al., 1995) and speci®c expression of PML was detected in myeloid cells (Daniel et al., 1993) . PML contains a number of clearly de®ned structural motifs, which are chie¯y encoded by the 5'-exons of this gene. The N-terminal proline rich domain is encoded by exon 1, the RING ®nger and the B1 and B2 boxes, which are rich in cystein residues, are mainly encoded by exons 2 and 3, and the a-helical coiled-coil domain is essentially encoded by exon 3 (see Figure 3) . Interestingly, in addition to PML, two other RING ®nger genes when translocated to other chromosomal loci are expressed as fusion proteins with transforming activities (Miki et al., 1991; Takahashi et al., 1988) .
The mechanism by which the t(15;17) translocation occurs is not known. It may be that many illegitimate recombinations occur during normal cell division and are eliminated by DNA repair systems (Tashiro et al., 1994) . Those clones that contain the PML ± RARa transcript survive and have a growth advantage. More recent study found that the PML and RARa genes are physically adjacent to each other in chromatin (Neves et al., 1999) , this perhaps explaining the tendency of the two genes to rearrange. Recent analysis also found short stretches of identity between the PML and RARa genes in the breakpoint regions . It was proposed that random cleavage of the RARa and PML genes is followed by limited pairing of short stretches of homologous DNA, repair of the breaks and joining of the loci.
Locations of chromosomal breakpoints within the exon/intron structures of both genes have been extensively analysed Chen et al., 1991; Diverio et al., 1992; Pandol® et al., 1992) . Within the RARa gene, all breakpoints map to genomic sequences lying upstream of exon 4 which encodes the B-region of the RAR and N-terminal part of the DBD (Figure 2) . Consequently, the PML ± RARa fusion gene product always contains the same regions of RARa (B-F) containing its DNA and ligand binding domains. In contrast, the N-terminal PML sequences joined to B-F domains of the RARa show patient to patient variability determined by the position of the translocation breakpoint within the PML gene and by alternative exon splicing (see Figure 3) . Pandol® et al. (1992) described three breakpoint clusters within the PML gene located in intron 3 (bcr3), exon 6 (bcr2) and intron 6 (bcr1). The patients with chromosomal breakpoints in either bcr1 or bcr3 express either the long (PML ± RARaL) or short (PML ± RARaS) form of the PML ± RARa protein . The RNA encoding the PML ± RARaL protein can be alternatively spliced to give PML ± RARaM (medium), which is usually co-expressed with the L form in a given patient (see Figure 3 for schematic representations). Breakpoints lying within bcr2 delete the 5'-splice site from intron 6. This causes selection of a cryptic 5' splice site within the fusion gene, usually within the translocated RARa intronic sequences, and hence generation of a PML ± RARaV transcript with variable portions of PML exon 6 sequences joined in the correct reading frame with RARa exon 4 (B region). The PML ± RARaS protein contains nearly all of the structural motifs of both PML and RARa proteins (see Figures 1 ± 3 for comparison) . The PML ± RARaV and L isoforms also contain additional PML coding sequences. A major potential structural motif missing in the S isoform, but present in both the L and V isoforms, is a putative nuclear localization signal (NLS) located in the proximal region of PML exon 6. In addition, part of a-helical domain encoded by exons 3 ± 6, a serine/proline (S/P) rich region, located in distal PML exon 6, are absent in all S isoform and some V isoform cases (Gallagher et al., 1995) . The PML ± RARaS isoform is also missing a sumolation site and a caspase cleavage sequence. Internal splicing of portions of PML exon 3 led in one patient to a small PML ± RARa fusion protein which contained the RING ®ngers, B boxes and the ®rst two portions of the a-helical coiled-coil domain, representing the minimal PML moiety required for oncogenicity . PML ± RARaL isoform is expressed in approximately 55% of adult patients with APL, while the S and V isoforms are expressed in approximately 35% and 8% of patients, respectively (Fenaux and Chomienne, 1996; Kane et al., 1996; Slack et al., 1997) . In the pediatric population, the V isoform accounts for a larger proportion of cases than in adults (Kane et al., 1996) , with a corresponding decrease in the number of Figure 3 Schematic representations of the PML gene and protein as well as dierent PML ± RARa oncoproteins. PML exons 1 ± 9 are indicated by boxes (not drawn to scale), with dierent shading corresponding to various PML functional domains (as in Figure 1 ). Serine and proline (P/S) rich C-terminal sequences of PML, which are excluded from the PML ± RARa fusion proteins, are as indicated. Open triangles indicate boundaries between protein regions encoded in dierent PML exons. Black triangles denote fusion points between the PML and RARa protein sequences. Positions of three translocation breakpoint cluster regions (Bcr1 ± 3) within the PML gene are indicated. Bcr1, 2 and 3 lead to expression of long (PML ± RARaL), variable (PML ± RARaV) and short (PML ± RARaS) forms of the fusion oncoprotein. PML ± RARaM and PML ± RARaV(M) arise by alternative splicing of sequences encoded in exon 5 from the same transcript as the L and V forms, respectively PML ± RARaS cases. In APL cells, PML ± RARa is present in great excess over wild-type RARa, making it the predominant retinoid receptor in those cells (Jansen et al., 1995; Pandol® et al., 1992) .
Each t(15;17) APL patient exhibits a unique set of PML ± RARa fusion products indicating a single breakpoint with alternative splicing and highlighting the clonal nature of the disease. Detection of the PML ± RARa fusion transcripts by RT ± PCR is a sensitive (Chen et al., 1992) and speci®c test for the diagnosis of APL and can be used to measure minimal residual disease after chemotherapy, dierentiation therapy and bone marrow transplantation (Miller et al., 1993) . Reappearance of PML ± RARa transcripts in the marrow often precedes a leukemic relapse (Diverio et al., 1998; Fenaux and Chomienne, 1996) . Initial studies indicated that patients treated with ATRA who harbored the PML ± RARaS had a high likelihood of early death or relapse (Huang et al., 1993; Vahdat et al., 1994) . One in vitro study indicated that blasts from APL patients with the PML ± RARaV isoform had decreased ATRA sensitivity (Gallagher et al., 1995) . There was an association between the PML ± RARaS isoform and more primitive morphology (Al-Omar et al., 1997) and secondary cytogenetic abnormalities, possibly due to dysfunctions in DNA repair or cell cycle control, suggesting a biological dierences between the isoforms (Slack et al., 1997) . Despite these potential dierences among the PML ± RARa isoforms, numerous studies reported consistently good clinical outcomes in all APL patients Slack et al., 1997) , probably due to the highly eective nature of current therapy.
Depending on the position of the breakpoint in the RARa locus, the reciprocal RARa ± PML fusion gene generated in t(15;17) can lead to the expression of both RARa1-and RARa2 ± PML (breakpoints between exon 4 and exon 5) or only RARa1 ± PML (breakpoints upstream of exon 4) reciprocal chimeric proteins . RARa1 ± and RARa2 ± PML contain the A1 and A2 domains of the RARa proteins, rspectively, fused to a variable portion of PML, due to alternative splicing, including the serine/proline rich Cterminal domain. It is hard to predict the eects of RARa ± PML since the roles of the various C-termini of PML are not well understood. Although all of the t(15;17) positive APLs express one of the PML ± RARa species, the reciprocal RARa-PML gene is expressed only in approximately 80% of cases . The lack of RARa-PML expression in up to 20% of patients may re¯ect breakpoints in the RARa intron 1 (excluding any coding sequences from the fusion gene) or deletions within the derivative locus on chromosome 17q21. Therefore, it appears that in general expression of the reciprocal gene is not required for the development of APL. Consistently, there were cases of APL associated with non-reciprocal fusions of PML and RARa, which did not generate RARa ± PML fusion genes (Borrow et al., 1994; Hiorns et al., 1994) . Furthermore, there are no dierences in ATRA sensitivities or clinical outcomes between patients who do or do not express the RARa ± PML transcripts (Li et al., 1997b) . Transgenic mice harboring the RARa ± PML fusion did not develop leukemia but when crossed with PML ± RARa mice, leukemia developed with increased rate (Pollock et al., 1999) . Hence, the RARa ± PML may modestly contribute to the disease process, perhaps through interference with the p53 function (Fogal et al., 2000; Guo et al., 2000; Pearson et al., 2000) . It is worth noting, however, that PML ± RARa and RARa ± PML sequences, which were co-expressed in transgenic animals, were not exactly reciprocal (they derived from Bcr1 and Bcr3, respectively) and thus would have never been found together in a human APL.
The PLZF gene and its fusion with RARa
The promyelocytic leukemia zinc ®nger (PLZF) gene was identi®ed by its rearrangement in an APL with t(11;17)(q23;q21) (Chen et al., 1993a,b) . Since then 16 cases of of APL with a fusion between the PLZF and RARa genes were described (Culligan et al., 1998; Grimwade et al., 1997 Grimwade et al., , 2000 Jansen et al., 1999; Licht et al., 1995) . A series of cases collected by our group in 1995 indicated that these patients were resistant to ATRA and had a generally poor response to chemotherapy . More recently a case report indicated that one patient had a response to the combination of ATRA and G-CSF. The combination treatment led to the dierentiation of leukemic blasts in vitro, the appearance of mature myeloid cells in the peripheral blood of the patient and the disappearance of PLZF ± RARa transcripts from bone marrow specimens for 7 weeks (Jansen et al., 1999) . Another patient achieved a remission with concurrent ATRA and chemotherapy (Culligan et al., 1998) . Hence the ATRA resistance of this syndrome may not be absolute. A recent review of previously reported and new cases from the European working party on APL found that 0.8% of APL patients harbored the t(11;17)(q23;q21) translocation . In one case a cryptic translocation occurred yielding the PLZF ± RARa fusion but not the reciprocal RARa ± PLZF indicating that at least in some patients this PLZF ± RARa is sucient to cause disease. Promyleocytes from the newer cases, like those originally collected, did not respond to ATRA in vitro, however many of the patients did respond to conventional chemotherapy, sometimes in combination with ATRA, and achieved durable remissions. Hence this disease, in contrast to prior impressions, can be chemotherapy sensitive. Whether marginal sensitivity to ATRA aided in the response of these patients to treatment remains unclear. Re-review of the phenotypes of APL blasts from t(11;17)(q23;q21) patients indicated that these cells have a regular nucleus and abundant cytoplasm with either course granules or many ®ne granules . Few cases also had Auer rods. Like the usual cases of APL the promyelocytes were CD34 7 /CD13 + /CD33 + but, as reported in one of the original patients (Scott et al., 1994) , three other cases were positive for the CD56 NK cell antigen. It was proposed that due to their characteristic regular nuclei and unusual immunophenotype, cases of APL with t(11;17)(q23;q21) should be given the subclassi®cation M3r.
The PLZF gene, encodes for a zinc ®nger transcription factor (Chen et al., 1993b) of 673 amino acids with nine KruÈ ppel-like C 2 H 2 zinc ®nger motifs. The Nterminal 118 amino acids comprise a POZ (Pox virus and Zinc ®nger) or BTB (Broad Complex, tramtrack, Bric a Brac) domain. In addition to PLZF, at least one other gene encoding a POZ-domain and zinc ®nger protein (BCL-6) has been implicated in oncogenesis (Kerckaert et al., 1993; Ye et al., 1993) . PLZF and BCL6 were found to interact in vitro and in vivo in a MDS cell line with lymphoid and myeloid features and PLZF could recruit BCL6 devoid of its own POZ domain to a speckled nuclear structures (Dhordain et al., 2000) . The POZ domain mediates homo-and heterodimerization (Bardwell and Treisman, 1994) , can act as a transferable transcriptional repression domain (Chang et al., 1996; Numoto et al., 1993) and can be involved in chromatin remodeling (Ra et al., 1995) . The PLZF POZ domain forms a tight, highly intertwined dimer (Ahmad et al., 1998; Li et al., 1997a Li et al., , 1999 Melnick et al., 2000b) . The top portion of the dimer structure forms a groove exposed to solvent and is lined with conserved charged amino acids potentially representing a peptide binding site.
PLZF is localized to the nucleus Reid et al., 1995) and is phosphorylated on serine and threonine residues . Immuno¯uor-escent microscopy showed PLZF in a pattern of *50 small nuclear speckles , which are dependent on the presence of the POZ . In one study, PML and PLZF partially colocalized in the PML NBs (Koken et al., 1997) , wheras in another report they were found to exist in adjacent nuclear strucures . The PLZF ± RARa fusion did not co-localize with PML or delocalize PML from nuclear body structures Koken et al., 1997) indicating that disruption of the PML NB per se is not required for the development of APL. In contrast, in t(15;17) APL, PLZF appears de-localized into a microspeckled pattern that is identical to that of PML ± RARa Koken et al., 1997) .
PLZF mRNA is expressed in undierentiated myeloid cell lines and at lower levels in more dierentiated erythroleukemia, promyelocytic and monocytic cell lines as well as in peripheral blood mononuclear cells (Chen et al., 1993b; Reid et al., 1995) . PLZF is down-regulated during dierentiation of NB4 and HL60 cells (Chen et al., 1993b) , but is upregulated in the MDS cell line after treatment with calcium ionophore, perhaps recapitulating some aspect of monocyte development . CD34 + human progenitor cells could be immunostained with PLZF antisera in a distinct nuclear speckled pattern (Reid et al., 1995) . When such cells were placed into culture and allowed to dierentiate, PLZF levels declined with terminal dierentiation (M Hoatlin, personal communication) . PLZF expression may be important for the maintenance or survival of hematopoietic stem cells and/or early progenitors, appears down-regulated with dierentiation and may be reexpressed in monocytes.
During mouse embryogenesis PLZF is expressed in a segmental pattern in the nervous system. Dynamic and rhombomere speci®c expression of PLZF during hindbrain development suggested that it may regulate transcription of the hoxb2 gene. A PLZF DNA binding site was found in the hoxb2 5' anking region and PLZF could repress the hoxb2 promoter in co-transfection assays . PLZF expression is also notable in the limb buds where hox genes help to guide the development and mice lacking PLZF (Barna et al., 2000) display homeotic limb defects including the presence of extra as well as transformed digits. This phenotype was associated with a more anterior pattern of expression of some hoxd genes in the developing hind limb bud, suggesting that PLZF could globally inhibit the expression of this class of hox genes. Decreased expression of morphogenic protein 7 (Bmp7) gene, which controls cell proliferation and programmed cell death in the developing limb, was also noted. The limb buds of PLZF null mice also showed increased proliferation and decreased apoptosis consistent with our data demonstrating PLZF to be a growth suppressor (see below). Spinal homeotic changes were noted and were associated with a more posterior expression boundary for the hoxc6 and hoxc8 genes. PLZF null mice have not exhibited an obvious hematopoietic phenotype, nor have they developed leukemia nor other tumors. This does not rule out a role for PLZF in hematopoiesis. FAZF/ROG, a gene that encodes a protein with expression patterns and DNA binding speci®cities highly similar to those of PLZF (unpublished results), might partially compensate for the lack of PLZF during development (Hoatlin et al., 1999; Miaw et al., 2000) . These data do indicate, however, that as suspected and found for many other leukemia-associated proteins (Look, 1997) , such as MLL (Yu et al., 1995) , HOX genes may be the major targets of PLZF and its fusion protein with RARa.
Like PML, PLZF can repress cell growth. 32DCL3 cells, overexpressing the PLZF protein were highly growth inhibited, accumulated in G1, traversed S phase slowly and had an increased rate of apoptosis (Shaknovich et al., 1998) . PLZF expression inhibited myeloid dierentiation induced by G-CSF or GM ± CSF and led to the up-regulation of the early hematopoietic marker Sca1. Acute infection of myeloid cells with a PLZF-containing retrovirus was associated with growth arrest of cells in the S phase of the cell cycle, implicating cyclin A as a potential target. Fibroblasts expressing PLZF showed blunted induction of cyclin A when stimulated into the cell cycle. PLZF can bind and repress the cyclin A2 promoter (Yeyati et al., 1999) and growth suppression by PLZF was overcome by enforced expression of cyclin A2. This suggests that PLZF may inhibit cell growth by altering the expression of cell cycle regulators. PLZF also protected 32D cells (Shaknovich et al., 1998) from apoptosis due to factor withdrawal. This has led us to hypothesize that PLZF plays a role in quiescence and resistance to apoptosis exhibited by hematopoietic stem cells. Down-regulation of PLZF during myeloid dierentiation may be accompanied by cycles of committed cell division. It is possible that PLZF is a tumor suppressor disrupted by t(11;17)(q23;q21) in APL. The PLZF ± RARa fusion proteins resulting from this translocation may act as dominant negative inhibitors of PLZF. In fact, heterodimerization between PLZF ± RARa and PLZF seems preferential to the formation of PLZF homomeric complexes . Hence, high-level expression of PLZF ± RARa in t(11;17)(q23;q21) blasts might sequester PLZF from binding to its natural target genes and/ or bind to limiting quantities of PLZF transcriptional co-factors (Ruthardt et al., 1997) . Continuing our search for PLZF target genes using cDNA microarray analyses we have found that c-myc expression is dramatically inhibited in a U937 cell lines induced to express PLZF (McConnell et al., 2000) . This correlates with a PLZF binding site (see below) in the c-myc promoter and the ability to detected it in a chromatin immunoprecipitation assay using PLZF antisera. Hence PLZF may inhibit proliferation by inhibiting the expression of multiple stimulators of the cell cycle.
From site selection and other experiments Ivins and Zelent, 1998; Sitterlin et al., 1997) a consensus sequence for PLZF binding of GTAC T / A G-TAC can be derived. Such sites can be recognized by the C-terminal four zinc ®ngers retained in the RARa ± PLZF fusion protein Sitterlin et al., 1997) . This suggests that the N-terminal zinc ®ngers of PLZF might not bind to DNA but participate in protein ± protein interactions. Reporter genes containing PLZF sites (David et al., 1998; Guidez et al., 1998) are repressed by co-expressed PLZF protein. In contrast, the RARa ± PLZF fusion protein activates such reporters while PLZF ± RARa has no eect . Hence the RARa ± PLZF protein could act in a dominant negative manner, binding and altering transcription of PLZF target genes. The PLZF protein was found to contain two separable transcriptional repression domains (RPD1 and 2, see Figure 4 ), one of which overlaps the POZ domain (Li et al., 1997a) . Point mutations in the POZ domain abrogate repression by PLZF (Melnick et al., 2000b) revealing that the dimerization function of this domain is required for full transcriptional repression of the isolated POZ region, as well as for repression by the full-length PLZF protein. In addition, dimerization through the POZ domain was required for the ability of PLZF to form high molecular weight DNA-protein complexes that contain cdc2 and for its biological activity (Melnick et al., 2000b) .
Repression by PLZF was shown to involve interactions with a number of co-repressors (mSin3A, N-CoR, SMRT) and histone deacteylases and was enhanced by co-expression of co-repressors and partially blocked by the HDAC inhibitor trichostatin A (David et al., 1998; Grignani et al., 1998; Guidez et al., 1998; Hong et al., 1997; Lin et al., 1998; Wong and Privalsky, 1998) . PLZF was reported to co-localize to the same nuclear sub-location as the SMRT co-repressor (Lin et al., 1998) . More recently histone dacetylases were found to co-localize with SMRT in such structures and enzymatic activity of the HDACs was required for their integrity (Downes et al., 2000) . Together these ®ndings suggest that PLZF and other repressor and or corepressor proteins may be recruited through the POZ domain to a nuclear repressor organelle complex in order to inhibit their target genes. Recently we have found that the ETO protein which is fused to AML1 in t(8;21)-associated AML and binds to PLZF primarily through RPD2, may serve as an additional PLZF corepressor (Melnick et al., 2000b) . It should be noted however, that in addition to HDAC recruitment other mechanisms of transcriptional repression by PLZF could be at play. For example, cdc2, which seems to (Long et al., 1998) . The t(11;17)(q23;q21) fusion yields two reciprocal transcripts (Chen et al., 1993b; Licht et al., 1995) . The resulting PLZF ± RARa fusion contains the entire Nterminal transcriptional eector region of PLZF and the ®rst two zinc ®ngers and in one case due to an alternative 3' breakpoint in the PLZF gene, three zinc ®ngers (see Figure 4) . In four of seven cases tested, a reciprocal RARa ± PLZF transcript was detected, linking the ligand independent activation domain of RARa (Nagpal et al., 1992) to the last seven PLZF zinc ®ngers. PML ± RARa and PLZF ± RARa have some similarities as aberrant receptors. Both fusion proteins can bind as homodimers to retinoic acid response elements (RARE) Hauksdottir and Privalsky, 2001; Licht et al., 1996; Perez et al., 1993) . In PML ± RARa this is mediated by the coiled-coil motif, and in PLZF by the POZ domain. In combination with RXR PLZF ± RARa forms multiple DNA-protein complexes, but the PLZF ± RARa/RXR heterodimer binds to RAREs with higher anity than PLZF ± RARa homodimers Licht et al., 1996) . The PLZF ± RARa/RXR heterodimer bound to the RARE less eciently than wild-type RXR/RARa perhaps due to the ability of the POZ domain to multimerize and preclude ecient DNA binding (Bardwell and Treisman, 1994) . Hence PLZF ± RARa might sequester limiting amounts of RXRa, an essential co-factor for RARa function. Furthermore, PLZF ± RAR/RXR heteromers also bound to non-consensus RAREs, potentially contributing to leukmogenesis by misdirecting the chimeric protein to novel genes (Hauksdottir and Privalsky, 2001; So et al., 2000) . Like PML ± RARa, PLZF ± RARa is relatively weak trans-activator (Chen et al., 1994b; Dong et al., 1996; Licht et al., 1996) and serves as a dominant negative inhibitor of wild-type RARa. Curiously, inhibition of wild-type RARa function was partially dependent on the presence of the ®rst two PLZF zinc ®ngers, present in the fusion protein. When the POZ domain and ®rst two PLZF zinc ®ngers were deleted from the fusion protein, PLZF ± RARa became an ecient activator of ATRAmediated transcription . As for PML ± RARa, repression by PLZF ± RARa is predominantly due to its high anity for the HDAC containing co-repressor compexes (David et al., 1998; Grignani et al., 1998; Guidez et al., 1998; He et al., 1998; Hong et al., 1997; Lin et al., 1998 ). This appears to be caused by the presence of four docking sites for co-repressors on each oncoprotein homodimer rather than two sites found in normal RXR/RAR heterodimers (Lin and Evans, 2000) . However, due to the ability of the PLZF POZ domain to bind the corepressors in an ATRA insenstive manner, while PML ± RARa releases these factors in the presence of 10 76 M ATRA, PLZF ± RARa does not Guidez et al., 1998; He et al., 1998; Hong et al., 1997; Lin et al., 1998) . Additional binding of ETO co-repressors to the RPD2 of PLZF may contribute to its overall strength of transcriptional repression and insensitivity to ATRA (Melnick et al., 2000a,b) . HDAC inhibitors, such as trichostatin A and sodium butyrate, allowed cells harboring PLZF ± RARa to respond to ATRA, presumably by inactivating the corepressor complexes bound to the POZ domain He et al., 1998; Lin et al., 1998) .
Transgenic animals harboring PLZF ± RARa developed a CML-like syndrome rather than APL (Cheng et al., 1999; He et al., 1998) . Unlike PML ± RARa transgenic mice, the PLZF ± RARa mice did not achieve durable CR after ATRA treatment, although cells did show some evidence of dierentiation and leukemic cells from the mice treated with ATRA dierentiated ex vivo . The relative insensitivity of the disease correlates with the impaired ability of PLZF ± RARa to transactivate due to (Koken et al., 1999) , no response of the PLZF ± RARa mice could be found. This could be due to a qualitative dierence in the degradation of these proteins induced by ATRA. A speci®c cleavage in the PML ± RARa fusion is induced by ATRA that can yield a protein that likely is devoid of most of the PML moiety and can likely transactivate RARa target genes. In contrast, PLZF ± RARa appears to be completely degraded by RARa with no such intermediate product, hence a transient boost in RARa target gene expression may not be expected in these cases. Though helping to explain the response to ATRA, these animal model do not explain the poor response of some t(11;17) (q23;q21) patients to chemotherapy and the complete resistance of fresh APL cells to high doses of ATRA in vitro (Guidez et al., 1994; Licht et al., 1995) . These ®ndings implicate the reciprocal RARa ± PLZF protein in the aggressive nature of PLZF ± RARa associated APL. The reciprocal transcript encoding RARa ± PLZF is consistently expressed in nearly all of the t(11;17)(q23;q21) patients (Grimwade et al., 1997; Licht et al., 1995) . The seven zinc ®ngers of RARa ± PLZF can bind to the same site as full-length PLZF Li et al., 1997a) . While PLZF represses gene transcription, RARa ± PLZF activates it (Li et al., 1997a) . Whereas PLZF is a growth suppressor, RARa ± PLZF activates expression of cyclin A2 (Yeyati et al., 1999) and enhances cell growth (P Yeyati, R Shaknovich, J Licht, unpublished results). Hence t(11;17)(q23;q21) may be an ATRA and chemotherapy resistant disease due to the presence of two oncogenes. PLZF ± RARa blocks the dierentiation inducing action of ATRA, while RARa ± PLZF may activate cell cycle regulators, blocking the antiproliferative eects of ATRA. In accordance with this idea, mice harboring the RARa ± PLZF protein develop a myeloproliferative syndrome and splenomegaly (He et al., 2000) . When PLZF ± RARa mice were crossed with RARa ± PLZF mice, leukemic latency at 6 months and penetrance of 100% did not change. However, there was a change in the morphology of the leukemia that developed. There was a doubling of promyelocytes and blasts in the marrows of the double transgenic mice to about 40%, associated increased expression of early dierentiation markers c-kit and CD34. Cells from the double trangenic mice had a higher proliferative index, lower sensitivity to apoptosis induction and less dierentiation in vitro in response to ATRA than cells derived from single transgenic PLZF ± RARa mice (He et al., 2000) . Remarkably an almost identical phenotype was seen when PLZF ± RARa trangenic mice were bred into the PLZF null background. This information is in accordance with our earlier results suggesting that RARa ± PLZF is a dominant negative form of PLZF and a growth activator. It is possible that through aberrant expression of PLZF targets such as HOX genes, cyclins and other cell cycle regulators, the presence of both fusion genes lead to a more aggressive and undierentiated form of leukemia.
Nucleophosmin and NPM ± RARa
In t(5;17) associated APL, RARa is translocated to a region on chromosome 5q35 containing the ubiquitously expressed and evolutionarily conserved nucleophosmin (NPM) gene (Redner et al., 1996b) . In hematologic malignancies NPM is also fused to genes other then RARa, as in the t(2;5)(p23;q35) translocation found in Ki-1 + anaplastic large cell lymphoma, for example (Morris et al., 1994; Shiota et al., 1995) . In this situation, NPM is linked to Alk, a gene encoding a membrane spanning tyrosine kinase (Morris et al., 1994) , which is normally not expressed in lymphoid tissue (Iwahara et al., 1997) . As a result, the ubquitously expressed NPM gene drives the expression of an aberrant fusion tryosine kinases (Bischof et al., 1997; Shiota et al., 1995) . In the t(3;5)(q25.1;q34) translocation, found in myelodysplasia and M6-AML, a larger 175 amino acid portion of NPM is linked to the MLF1 gene, which encodes an abundant cytoplasmic protein of unknown function (Yoneda-Kato et al., 1996) . NPM was initially isolated as a nucleolar phosphoprotein in hepatoma cells (Hernandez-Verdun et al., 1982; Olson et al., 1974) . The human NPM gene spans 25 kb, consists of 12 exons (Chan et al., 1997) and alternative splicing of its transcripts yields two major isoforms, which dier in their C-terminal region (Chan et al., 1997 (Chan et al., , 1989 Lee and Welch, 1997) . Structural features of NPM include: two Asp/Glu rich acidic domains, potential binding sites for other proteins; a bipartite nuclear localization signal (NLS); a metal binding motif; an ATP binding site; phosphorylation sites for cdc2 kinase and casein kinase II and a binding site for proteins which contain nucleolar localization signals (Chan et al., 1986a (Chan et al., ,b, 1989 . Both isoforms reversibly multimerize to a hexameric state via the N-terminal domain (Chan and Chan, 1995) . NPM is localized most prominently to areas of the nucleolus associated with ribonucleoprotein (RNP) processing (Dumbar et al., 1989; Smetana et al., 1984) . NPM functions as part of a transport system used by ribosomal precursors and other proteins to shuttle between the cytoplasm and nucleolus (Szebeni et al., 1997) .
NPM levels are augmented in proliferating cells (Derenzini et al., 1995) and leukemic blasts (Kondo et al., 1997) , perhaps due to an increased requirement for ribosomal precursors. However, overexpression of NPM transformed NIH3T3 (Kondo et al., 1997) cells, while down-regulation of NPM delayed cell entry into mitosis (Jiang and Yung, 1999) , suggesting that NPM could have an active role in growth control. In support of this concept, it was found that NPM binds to the tumor suppressor IRF-1 and inhibits its ability to activate genes, which mediate the anti-proliferative eect of IFN (Kondo et al., 1997) . Furthermore, NPM binds to transcription factor YY1, involved in cell growth, changing it from a repressor to an activator of transcription (Inouye and Seto, 1994; Shi et al., 1997) . ATRA-induced dierentiation of HL60 cells, but not growth arrest by serum withdrawal, resulted in down regulation of NPM (Hsu and Yung, 1998) . When cellular NPM levels were decreased by an antisense oligonucleotide, ATRA-induced dierentiation was augmented (Hsu and Yung, 1998) while overexpression of NPM prevented dierentiation (Hsu and Yung, 2000) . Growth suppressive IRF-1 is up-regulated by ATRA during myeloid dierentiation, in opposition to the eect of NPM (Matikainen et al., 1996) . These results support a role for NPM in both control of cell growth and cross-talk between the retinoid and IFN regulatory pathways.
NPM expression peaks at S or G 2 phase and is at minimal levels in G 0 (Feuerstein et al., 1988; Sirri et al., 1997) . This might be related to the fact that NPM speci®cally stimulates the activity of DNA polymerase a (Takemura et al., 1994) or may simply be a re¯ection of the metabolic demand of the cell. During G 2 and M phase, NPM is heavily phosphorylated by cdc2 (Peter et al., 1990) . During M-phase progression NPM associates with perichromosal regions and pre-nucleolar bodies thus functionally linking the processes of nucleolar disassembly to mitotic chromosome condensation (Peter et al., 1990) . A fraction of the protein can also co-localize with NuMA (see below) at the spindle poles during mitosis (Zatsepina et al., 1999) . Recently NPM was identi®ed as the major substrate of cyclin E/cdk2 in centrosomes. NPM associated with only unduplicated centrosomes and it was released from the duplicated structures after phosphorylation (Okuda et al., 2000) . The function of NPM in the centrosome may relate to its chaperone activity, keeping proteins in their proper conformation, and may regulate the duplication of centrosomes.
NPM is preferentially dephosphorylated and degraded during apoptosis and cell damage (Taw®c et al., 1995) . NPM reversibly de-localizes from the nucleolus to the nucleoplasm when cells are exposed to conditions that discourage DNA or RNA synthesis (Yung et al., 1985a,b) or encourage terminal cell division (Chan et al., 1987) . Delocalization of NPM from the nucleolus is an early event in drug-induced apoptosis . Whether the delocalization is a result of or a trigger for further cell death events is not certain. However, protection of HL60 cells from apoptosis induced by drugs and potentiation of cell death due to serum withdrawal by overexpression of sense and anti-sense NPM transcripts, respectively, is consistent with its regulatory role in apoptoisis (Chou and Yung, 2001; Liu et al., 1999) . Thus like PML, NPM underogoes changes with cell stress, indicating that both proteins may measure or control cell homeostatic processes. High levels of NPM found in cancer cells might promote both cell proliferation and prevent programmed cell death. Recently the p14 ARF protein was found to partially co-localize with NPM in the nucleolus (Lindstrom et al., 2000) . Whether the two proteins directly interact or whether NPM has any role in the ARF/MDM2/p53 regulatory circuit (reviewed in Sherr and Weber, 2000) is unknown.
The t(5;17)(q35;q21) translocation was ®rst described in a 2 year-old girl with APL (Corey et al., 1994) who achieved cytogenetic remission after treatment with ATRA and chemotherapy. Blasts from this index patient, when thawed and treated with ATRA, dierentiated into mature granulocytes (Redner et al., 1997) . Subsequently only two other cases were con®rmed at the molecular level , one of whom has had a prolonged survival after ATRA and bone marrow transplantation (Hummel et al., 1999) and the other remaining in CR after chemotherapy . This gene rearrangement joins the NPM gene 5' to exon 3 of RARa, in a manner similar to the other APL fusions (Redner et al., 1997) , yielding two isoforms of the chimeric oncoprotein. Both forms contain the oligomerization domain of NPM. Like PML ± RARa and PLZF ± RARa, the NPM ± RARa fusion acts as a ligand-dependent transcriptional activator when coexpressed with reporter genes containing RAREs, yet can act as a dominant negative inhibitor of wild-type RARa through aberrant interaction with co-repressor molecules (Redner et al., 2000; So et al., 2000) . Like other APL fusions, NPM ± RARa could form homodimers, thus exposing the RARa moiety in such a way as to oer extra binding sites for co-repressors, necessitating pharmacological doses of ATRA to release them and recruit co-activators to the fusion proteins. Enforced expression of NPM ± RARa in U937 cells blocked monocytic dierentiation in response to vitamin D 3 and TGFû (Redner et al., 1996a) . It was further found that as PML ± RARa, PLZF ± RARa and NPM ± RARa could enhance the proliferation of primitive marrow progenitor cells. Treatment of these cells with ATRA, induced dierentiation and inhibited cell growth (Du et al., 1999) . A transgenic model of t(5;17)-APL was recently created utilizing the cathepsin G promoter. These mice developed an APL like syndrome after a latent period and blasts derived from these animals were ATRA sensitive (Cheng et al., 1999) .
Similarly to PML ± RARa and PLZF ± RARa, NPM ± RARa is expressed in a microspeckled pattern throughout the nucleus (Hummel et al., 1999) and APL blasts from t(5;17) patients exhibited a normal PML NB con®guration Hummel et al., 1999) , supplying additional evidence that disruption of the PML NB is not required for the pathogenesis of APL. However, PLZF was de-localized in t(5;17) APL cells in a pattern distinct from its wild-type distribution in progenitors (Hummel et al., 1999) , lending support for a broader role of the PLZF protein in APL. A reciprocal RARa ± NPM mRNA, leading to fusion between the A domain of RARa and the acidic domains, NLS and the rest of the C-terminus of NPM, was identi®ed in the index t(5;17) patient (Redner et al., 1996b) and one other case of t(5;17) APL . The importance of this putative protein is unknown.
Nuclear matrix ± Mitotic apparatus protein (NuMA)
NuMA is an abundant, conserved and ubiquitously expressed protein involved in the completion of mitosis and re-formation of nuclei in the post-mitotic daughter cells (Compton and Cleveland, 1994; Compton et al., 1992; He et al., 1995; Saredi et al., 1996) . The NuMA gene, located on chromosome 11q13 (Sparks et al., 1993) , encodes a protein of 2115 amino acids with a molecular weight of approximately 230 kDa. Alternative splicing can also yield 1776 and 1763 amino acid proteins (Tang et al., 1993 (Tang et al., , 1994 . The NuMA protein is divided into two globular domains at either end of the protein, with a central coiled-coil region of 1485 amino acids (Compton et al., 1992; . The coiled-coil motifs likely mediate protein homo-and hetero-association (Harborth et al., 1995; . The C-terminal region contains basic sequences, motifs for phosphorylation by cdc2 and other kinases (Hsu and Yeh, 1996; , and sequences which confer localization to the nucleus (NLS) and mitotic spindle (Compton and Cleveland, 1993; . NuMA might play a structural role in anchoring the spindle poles in the cell (Dionne et al., 1999) .
NuMA is regulated across the cell cycle by posttranslational modi®cations. For example, NuMA is phosphorylated by the cdc2/cyclin B regulatory kinase at the initiation of mitosis (Hsu and Yeh, 1996; Saredi et al., 1997) and associates with the spindle microtubules. NuMA may be required for the formation of the nuclear spindle poles and spindle aster, as well as for the organization of daughter nuclei towards the end of cell division (Gordon et al., 2001; Lyderson and Pettijohn, 1980; . At the end of mitosis, NuMA undergoes proteolytic cleavage and dephosphorylation (Hsu and Yeh, 1996; Saredi et al., 1997) . As cells progress towards G 1 , the remaining NuMA reverts to an insoluble form, yielding a ®brous network of 12 arm oligomers that may play a structural role in forming the nuclear scaold (Harborth et al., 1999) . In interphase cells NuMA is localized in diuse and speckled nuclear patterns (Kempf et al., 1994; Lyderson and Pettijohn, 1980) and like the other RARa partners (see Table 1 ) in APL it is associated with the nuclear matrix (Zeng et al., 1994) . NuMA speci®cally attaches to DNA matrix attachment regions (MAR), important for chromatin compaction and isolation of transcriptionally active loops of DNA (Luderus et al., 1994; Tsutsui et al., 1993) . NuMA has been found to bind at least one putative transcriptional regulator and hence could participate in the regulation of transcription .
NuMA is an early target for proteolysis by caspase-3 and caspase-6 (Zweyer et al., 1997) , yielding a proteolytic product (Casiano et al., 1996; Hsu and Yeh, 1996) , that could act as a dominant negative factor, disrupting normal nuclear structure. Release of NuMA from the DNA matrix attachment regions may facilitate the DNA fragmentation characteristic of apoptosis (Gueth-Hallonet et al., 1997) . In summary, NuMA is a structural component of the cell that responds to cell cycle signals on cue rather than a controlling factor in cell proliferation. It seems unlikely that inhibition of NuMA function might contribute to oncogenesis.
The NuMA ± RARa fusion protein was described in a 6 month old boy with APL harboring a translocation t(11;17)(q13;q21) (Wells et al., 1997) . The patient had ATRA therapy and was disease free at 24+ months after a bone marrow transplant (Wells et al., 1996) . The t(11;17)(q13;q21) results in a 2286 amino acids protein predicted to consist of 1883 amino acids of NuMA, including its N-terminal globular and coiled-coil domains, fused to the RARa domains B-F (Wells et al., 1997) . NuMA-RARa localized to sheetlike nuclear aggregates in leukemic cells from the patient, but the PML-NB structures remained unperturbed. Introduction of C-terminal mutants of NuMA into cells completely disrupts mitosis (Compton and Cleveland, 1993; Maekawa and Kuriyama, 1993) and it is surprising that the existence of NuMARARa is even compatible with cell division.
The most likely mechanism of the NuMA ± RARa action is interference with nuclear receptor function. Although no functional data for the NuMA ± RARa fusion are yet available, it is likely that, as the other RARa fusion proteins, NuMA ± RARa is a dominant negative retinoid receptor (see Table 2 ). Like PML, PLZF and NPM, NuMA can multimerize (Harborth et al., 1995; . NuMA ± RARa might thus sequester RARa partner proteins and/or have aberrant anity for nuclear receptor co-activators or co-repressors due to the formation of homodimers (Lin and Evans, 2000) . Like PML, NuMA is a component of the nuclear matrix and NuMA ± RARa might further inhibit RARa function by con®nement of RARa co-factors in a nuclear compartment dierent from that usually occupied by the wild-type RARa. It is unknown whether a reciprocal RARa ± NuMA transcript is expressed in this disease. In fact, there might be selective pressure against this protein as it could represent a detriment to mitosis.
STAT5b ± RARa fusion
The newest fusion partner with RARa, identi®ed in a patient with M1 AML but with a proportion of blasts exhibiting microgranular APL morphology (Arnould et al., 1999) , is the STAT5b gene. Leukemic blasts from this patient failed to respond to ATRA in vitro. Like RARa the STAT5b gene is localized on chromosome 17q21.1-21.2 and the two genes are estimated to be about 3Mb apart. The patient with the STAT5b ± RARa fusion had a deletion of chromosome 17 leading to the creation of a fusion intron linking the STAT5b and RARa loci. As in the case of other forms of APL, the breakpoint in the RARa locus was within the same highly localized region 5' of the third coding exon. No reciprocal RAR ± STAT5b transcript was detected.
The seven members the mammalian STAT proteins are transcription factors which are resident in the cytoplasm until they are phosphorylated on speci®c tyrosine residues following activation of various cytokine receptors. Binding of a given cytokine to a speci®c receptor induces its dimerization and, for a receptor with an intrinsic kinase activity, activation of tyrosine kinase. Receptors without intrinsic kinase activities are non-covalently attached to JAK kinases, which when brought into close proximity can in a similar way cross-phosphorylate and activate each other. STAT5b, like other STAT proteins, binds to the JAK kinase through an SH2 domain and then is itself tyrosine phosphorylated at a C-terminal residue. STAT5b can then homodimerize, migrate to the nucleus and bind to a GAS element (Darnell, 1997) .
STAT5b is widely expressed in a number of tissues including hematopoietic progenitors and can be activated by a number of cytokines including prolactin, GM-CSF, EPO and IL-3 (Chretien et al., 1996; Dong et al., 1998; Mui et al., 1996) . STAT5b is very similar to STAT5a but diers in the C-terminal activation domain (Lin et al., 1996; and reviewed in Lin and Leonard, 2000) . STAT5 was originally identi®ed as a factor important in mammary gland response to prolactin and knockout studies showed that STAT5a is required for breast development and lactation (Teglund et al., 1998) . STAT5b null mice have a defective response to growth hormone, no overt quantitative hematopoietic defects, but have a defect in NK cell killing (Imada et al., 1998) . Compound null mice have a severe defect in response to CSFs and a de®ciency in T cells (Teglund et al., 1998) . STAT5b target genes relevant to hematopoiesis include c-myc and the IL-2 receptor (Matikainen et al., 1999) , and STAT5 activation was recently identi®ed as a crucial function of the bcr-abl oncoprotein (Gesbert and Grin, 2000; Nieborowska-Skorska et al., 1999) , although this latter point remains somewhat controversial (Sexl et al., 2000) . Stat5b de®cient mice show an increase in apoptosis in response to GM-CSF induced dierentiation (Kieslinger et al., 2000) . In addition, Stat5b can induce the expression of the anti-apoptotic Bcl-x gene and therefore may play a role in preventing programmed cell death during terminal myeloid dierentiation. Stat5b may also promote cell survival by acting as an intermediate activating the PI3 kinase/ AKT signaling pathways (Santos et al., 2001) . Stat5b may also promote oncogenesis, since the protein could accelerate transformation and cell cycle progression induced by v-src, while a dominant negative form of the protein could inhibit transformation (Kazansky and Rosen, 2001) . Hence like PLZF, STAT5b represents a transcription factor fused to the RARa, which itself may play a role in normal and malignant blood development.
The STAT5b ± RARa fusion contains the majority of the STAT5b protein. The N-terminus consist of a coiled-coil region that mediates dimerization and interaction with a protein called Nmi1, which enhances STAT binding to the p300/CBP co-activators . This domain might allow the STAT5b ± RARa to sequester co-activators from the remaining wild-type receptor in the cell. Located centrally in the protein is a DNA binding domain followed by SH3 and truncated SH2 domains. The STAT proteins dimerize through their SH2 domains after they become phosphorylated. The C-terminal tyrosine 699, required for STAT5b activation, is missing in the fusion protein as is a more C-terminal serine residue whose phosphorylation activates STAT5b transcription function. Nevertheless, a preliminary report indicates that the STAT5b ± RARa fusion can form a homodimer as well as a heterodimer with RXR on RAREs (Dong and Tweardy, 2000) and can act as a dominant negative form of RAR when co-expressed with wildtype receptor in a reporter assays. Deletion of the Nterminal coiled-coil region of the Stat5b protein prevented homodimer formation. Like other homodimeric forms of RARa in APL, the STAT5b-RARa fusion protein had a high anity for the SMRT corepressor, only releasing it at 10 76 M ATRA. As a heterodimer, the fusion had a high capacity for sequestration of RXR. Hence this chimera seems quite similar in function to the other APL fusion oncoproteins. A further potential of the STAT5b ± RARa protein, however, is its ability to interfere with STAT signaling. STAT5b ± RARa retains the N-terminal portion of the STAT5b SH2 domain in the fusion protein and could compete with the wild-type STA5b for docking with cytokine receptors. However, in the index patient the STAT5b protein was localized in the nucleus while in control marrow cells STAT5b was localized to the cytoplasm (Arnould et al., 1999) . Nevertheless, it was shown that the STAT5b ± RARa fusion could heterodimerize with wild-type STAT5b in transfected cells and inhibited prolactin-stimulated gene expression (Dong and Tweardy, 2000) . In contrast, the STAT5b ± RARa fusion enhanced IL6-mediated transcription from a Stat3-dependent promoter. The potential pleiotropic eects of the STAT5b ± RARa fusion might deregulate the ability of STAT5 or other STATs to respond to cytokines and lead to altered cell proliferation and/or survival. This may explain the retinoic acid resistance of the patient who had this variant form of APL, despite the fact that the STAT5b ± RARa fusion appears to have very similar properties as PML-RARa. These ®nding also may prompt an examination of STAT signaling in other forms of APL, since its has been shown that cytokines can augment the dierentiation eects of ATRA (Nakamaki et al., 1994) .
Summary
There are three axes to be investigated in understanding the pathogenesis of APL. Firstly, in all cases of APL RARa is fused to the partner (N) proteins, which can multimerize (see Tables 1 and 2 for dierences and similarities between N and N ± RARa proteins). Multimerization appears to mediate the abnormally high anity of the fusion proteins for corepressors. In addition, PLZF itself binds to corepressors prohibiting their full release at pharmacological doses of ATRA and leading to a resistant form of APL. These fusion proteins block the activation of critical genes required for myeloid dierentiation. The fusion proteins may also aect other transcriptional pathways via protein-protein interactions. Second, loss of one allele of the N partner gene could disable a growth suppressive pathway. Furthermore, the N ± RARa fusion might sequester the normal N product. Lastly, as in the case of RARa ± PLZF, the reciprocal RARa ± N fusion protein could act either as a dominant negative factor for the N protein or sequester RAR co-factors.
For the past 10 years the study of the molecular pathogenesis of APL is at the forefront of molecular medicine, as this disease has proven the concept of dierentiation therapy of leukemia (Waxman, 1978) . The study of the resistant and sensitive forms of APL, has indicated the critical importance of aberrant transcriptional repression as a root cause of leukemia. This led to the use of the histone deacetylase inhibitor phenyl butyrate in combination with ATRA as a form of targeted`transcription therapy' in a patient with resistant APL (Warrell et al., 1998) and to the further development of HDAC inhibitors, such as SAHA , for dierentiation therapy. It should be noted, however, that compounds without any HDAC inhibitory activities, such as HMBA (a compound structurally related to SAHA) or dithiophenes for example, exert the same eects on enhancing ATRA mediated dierentiation of APL cells (Chen et al., 1994a; Waxman et al., 1999) . It remains a sound possibility, therefore, that some eects of HDAC inhibitors on cell dierentiation may be mediated through additional mechanisms, which do not require inhibition of histone deacetylation per se. More recent work indicates existence of RAR independent and RXR plus PKA agonist dependent dierentiation pathway for APL (Benoit et al., 1999) and activation of this pathway could also overcome ATRA resistance. The same group has very recently reported that ATRA induced dierentiation of APL cells terminates with the induction of apoptosis through the paracrine activity of Apo-2L/TRAIL death ligand (Altucci et al., 2001) , suggesting the use of TRAIL in anti-APL therapies (Altucci et al., 2001; Zelent, 2001) . With the establishment of animal and cell models for sensitive and resistant forms of APL, the development of more eective therapies can be expected to continue. It is anticipated that therapeutic approaches that are discovered and developed through studies of APL will in the end ®nd a broader application in cancer treatment.
